Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Global immunization against AIDS: economic considerations

J C Petricciani1

  • 1Genetics Institute, Cambridge, MA 02140.

Vaccine
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The acceptability of continuous cell lines: A personal & historical perspective.

Cytotechnology·2012
Same author

An overview of viral and viral-like agents in cell culture systems.

Cytotechnology·2008
Same author

Recent trends in cell substrate considerations for continuous cell lines.

Current opinion in biotechnology·2001
Same author

Recombinant DNA vaccines and therapeutics.

Lancet (London, England)·2000
Same author

International acceptance of blood and blood products.

Developments in biologicals·2000
Same author

Cell substrates: lessons learned and challenges remaining.

Developments in biological standardization·2000
Same journal

Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].

Vaccine·2026
Same journal

Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.

Vaccine·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
See all related articles

Developing safe and effective human immunodeficiency virus (HIV) vaccines is crucial for ending the AIDS pandemic. Global immunization programs will require significant multi-billion dollar investment and early financial planning to ensure widespread vaccine access.

Area of Science:

  • Immunology
  • Global Health
  • Vaccinology

Background:

  • The AIDS pandemic remains a significant global health challenge.
  • Safe and effective human immunodeficiency virus (HIV) vaccines are considered essential for pandemic control.
  • A global immunization program for HIV vaccines could involve over 100 million individuals.

Purpose of the Study:

  • To highlight the critical need for early international consideration of financing strategies for global HIV vaccine programs.
  • To prevent delays in vaccine accessibility similar to past experiences with other vaccines.

Main Methods:

  • This is a conceptual analysis and policy recommendation based on existing knowledge and historical vaccine rollout challenges.
  • Review of potential scale and cost implications for a global HIV vaccine initiative.

Related Experiment Videos

Main Results:

  • Potential target populations for HIV vaccines exceed 100 million people.
  • The financial investment required for a global HIV vaccination program is estimated to be in the multi-billions of dollars.

Conclusions:

  • Proactive international financial planning is imperative for the successful and equitable distribution of future HIV vaccines.
  • Addressing funding strategies now can prevent significant delays in vaccine deployment and impact on the AIDS pandemic.